Pancreatoduodenectomy for Neuroendocrine Tumors in Patients with Multiple Endocrine Neoplasia Type 1: An AFCE (Association Francophone de Chirurgie Endocrinienne) and GTE (Groupe d'étude des Tumeurs Endocrines) Study.
Journal
World journal of surgery
ISSN: 1432-2323
Titre abrégé: World J Surg
Pays: United States
ID NLM: 7704052
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
accepted:
30
01
2021
pubmed:
3
3
2021
medline:
9
7
2021
entrez:
2
3
2021
Statut:
ppublish
Résumé
To assess postoperative complications and control of hormone secretions following pancreatoduodenectomy (PD) performed on multiple endocrine neoplasia type 1 (MEN1) patients with duodenopancreatic neuroendocrine tumors (DP-NETs). The use of PD to treat MEN1 remains controversial, and evaluating the right place of PD in MEN1 disease makes sense. Thirty-one MEN1 patients from the Groupe d'étude des Tumeurs Endocrines MEN1 cohort who underwent PD for DP-NETs between 1971 and 2013 were included. Early and late postoperative complications, secretory control and overall survival were analyzed. Indication for surgery was: Zollinger-Ellison syndrome (n = 18; 58%), nonfunctioning tumor (n = 9; 29%), insulinoma (n = 2; 7%), VIPoma (n = 1; 3%) and glucagonoma (n = 1; 3%). Mean follow-up was 141 months (range 0-433). Pancreatic fistulas occurred in 5 patients (16.1%), distant metastases in 6 (mean onset of 43 months; range 13-110 months), postoperative diabetes mellitus in 7 (22%), and pancreatic exocrine insufficiency in 6 (19%). Five-year overall survival was 93.3% [CI 75.8-98.3] and ten-year overall survival was 89.1% [CI 69.6-96.4]. After a mean follow-up of 151 months (range 0-433), the biochemical cure rate for MEN-1 related gastrinomas was 61%. In MEN1 patients, pancreatoduodenectomy can be used to control hormone secretions (gastrin, glucagon, VIP) and to remove large NETs. PD was found to control gastrin secretions in about 60% of cases.
Sections du résumé
AIM
To assess postoperative complications and control of hormone secretions following pancreatoduodenectomy (PD) performed on multiple endocrine neoplasia type 1 (MEN1) patients with duodenopancreatic neuroendocrine tumors (DP-NETs).
BACKGROUND
The use of PD to treat MEN1 remains controversial, and evaluating the right place of PD in MEN1 disease makes sense.
METHODS
Thirty-one MEN1 patients from the Groupe d'étude des Tumeurs Endocrines MEN1 cohort who underwent PD for DP-NETs between 1971 and 2013 were included. Early and late postoperative complications, secretory control and overall survival were analyzed.
RESULTS
Indication for surgery was: Zollinger-Ellison syndrome (n = 18; 58%), nonfunctioning tumor (n = 9; 29%), insulinoma (n = 2; 7%), VIPoma (n = 1; 3%) and glucagonoma (n = 1; 3%). Mean follow-up was 141 months (range 0-433). Pancreatic fistulas occurred in 5 patients (16.1%), distant metastases in 6 (mean onset of 43 months; range 13-110 months), postoperative diabetes mellitus in 7 (22%), and pancreatic exocrine insufficiency in 6 (19%). Five-year overall survival was 93.3% [CI 75.8-98.3] and ten-year overall survival was 89.1% [CI 69.6-96.4]. After a mean follow-up of 151 months (range 0-433), the biochemical cure rate for MEN-1 related gastrinomas was 61%.
CONCLUSION
In MEN1 patients, pancreatoduodenectomy can be used to control hormone secretions (gastrin, glucagon, VIP) and to remove large NETs. PD was found to control gastrin secretions in about 60% of cases.
Identifiants
pubmed: 33649917
doi: 10.1007/s00268-021-06005-7
pii: 10.1007/s00268-021-06005-7
pmc: PMC8093175
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1794-1802Références
Brandi ML, Gagel RF, Angeli A et al (2001) Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86:5658–5671
pubmed: 11739416
doi: 10.1210/jcem.86.12.8070
Marini F, Falchetti A, Del Monte F et al (2006) Multiple endocrine neoplasia type 1. Orphanet J Rare Dis 1:38
pubmed: 17014705
pmcid: 1594566
doi: 10.1186/1750-1172-1-38
Thakker RV, Newey PJ, Walls GV et al (2012) Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab 97:2990–3011
pubmed: 22723327
doi: 10.1210/jc.2012-1230
Ito T, Igarashi H, Uehara H, Berna MJ, Jensen RT (2013) Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger–Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors. Medicine (Baltimore) 92(3):135–181
doi: 10.1097/MD.0b013e3182954af1
Goudet P, Murat A, Binquet C et al (2010) Risk factors and causes of death in MEN1 disease. A GTE (Groupe d’Etude des Tumeurs Endocrines) cohort study among 758 patients. World J Surg 34(2):249–55
pubmed: 19949948
doi: 10.1007/s00268-009-0290-1
Sadowski SM, Triponez F (2015) Management of pancreatic neuroendocrine tumors in patients with MEN 1. Gland Surg 4(1):63–8
pubmed: 25713781
pmcid: 4321051
Pieterman CRC, de Laat JM, Twisk JWR, van Leeuwaarde RS et al (2017) Long-term natural course of small nonfunctional pancreatic neuroendocrine tumors in MEN1-results from the Dutch MEN1 Study Group. J Clin Endocrinol Metab 102(10):3795–3805
pubmed: 28938468
doi: 10.1210/jc.2017-00372
Triponez F, Sadowski SM, Pattou F et al (2018) Long-term Follow-up of MEN1 patients who do not have initial surgery for small ≤2 cm nonfunctioning pancreatic neuroendocrine tumors, an AFCE and GTE study: Association Francophone de Chirurgie Endocrinienne & Groupe d’Etude des Tumeurs Endocrines. Ann Surg 268(1):158–164
pubmed: 28263205
doi: 10.1097/SLA.0000000000002191
Tonelli F, Fratini G, Nesi G et al (2006) Pancreatectomy in multiple endocrine neoplasia type 1-related gastrinomas and pancreatic endocrine neoplasias. Ann Surg 244(1):61–70
pubmed: 16794390
pmcid: 1570585
doi: 10.1097/01.sla.0000218073.77254.62
Lopez CL, Waldmann J, Fendrich V et al (2011) Long-term results of surgery for pancreatic neuroendocrine neoplasms in patients with MEN1. Langenbecks Arch Surg 396(8):1187–1196
pubmed: 21805182
doi: 10.1007/s00423-011-0828-1
Lopez CL, Falconi M, Waldmann J et al (2013) Partial pancreaticoduodenectomy can provide cure for duodenal gastrinoma associated with multiple endocrine neoplasia type 1. Ann Surg 257(2):308–314
pubmed: 22580937
doi: 10.1097/SLA.0b013e3182536339
Eshmuminov D, Schneider M, Clavien et al (2018) Systematic review and meta-analysis of post-operative pancreatic fistula rates using the updates 2016 International Study Group pancreatic fistula definition in patients undergoing pancreatic resection with soft and hard pancreatic texture. HPB (Oxford) 20(11):992–1003
doi: 10.1016/j.hpb.2018.04.003
Thakker RV, Newey PJ, Walls GV et al (2012) Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). Endocrine Soc J Clin Endocrinol Metab 97(9):2990–3011
doi: 10.1210/jc.2012-1230
Cryer PE, Axelrod L, Grossman AB et al (2009) Endocrine society. Evaluation and management of adult hypoglycemic disorders: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 94(3):709–728
pubmed: 19088155
doi: 10.1210/jc.2008-1410
Gibril F, Schumann M, Pace A, Jensen RT et al (2004) Multiple endocrine neoplasia type 1 and Zollinger–Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature. Medicine (Baltimore) 83(1):43–83
doi: 10.1097/01.md.0000112297.72510.32
Metz DC, Cadiot G, Poitras P et al (2017) Diagnosis of Zollinger–Ellison in the era of PPIs. Int J Endocr Oncol 4(4):167–185
pubmed: 29326808
pmcid: 5757869
doi: 10.2217/ije-2017-0018
Lévy-Bohbot N, Merle C, Goudet P et al (2004) Prevalence, characteristics and prognosis of MEN 1-associated glucagonomas, VIPomas, and somatostatinomas: study from the GTE (Groupe des Tumeurs Endocrines) registry. Groupe des Tumeurs Endocrines. Gastroenterol Clin Biol 28(11):1075–81
pubmed: 15657529
doi: 10.1016/S0399-8320(04)95184-6
Couvelard A, Glucagonoma HO (2015). In: Stefano LR, Fausto S (eds) Pancreatic neuroendocrine neoplasms: practical approach to diagnosis, classification, and therapy. Springer, Switzerland, pp 81–87
doi: 10.1007/978-3-319-17235-4_9
Falconi M, Eriksson B, Kaltsas G et al (2016) ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Vienna Consens Conf Particip Neuroendocrinol 103(2):153–171
Clavien PA, Barjun J, Makuuchi M et al (2009) The Clavien–Dindo classification of surgical complications five-year experience. Ann Surg 250(2):187–196
doi: 10.1097/SLA.0b013e3181b13ca2
Bassi C, Marchegiani G, Dervenis C et al (2017) The 2016 update of the ISGPS definition and grading of postoperative pancreatic fistula: 11 years after international study group on pancreatic surgery. Surgery 161(3):584–591
pubmed: 28040257
doi: 10.1016/j.surg.2016.11.014
Wente MN, Veit JA, Bassi C et al (2007) Postpancreatectomy hemorrhage (PPH): an International Study Group of Pancreatic Surgery (ISGPS) definition. Surgery 142(1):20–25
pubmed: 17629996
doi: 10.1016/j.surg.2007.02.001
Wente MN, Bassi C, Büchler M et al (2007) Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery 142(5):761–768
pubmed: 17981197
doi: 10.1016/j.surg.2007.05.005
Jilesen AP, van Eijck CH, Hof KH et al (2016) Postoperative complications, in-hospital mortality and 5-year survival after surgical resection for patients with a pancreatic neuroendocrine tumor: a systematic review. World J Surg 40(3):729–748
pubmed: 26661846
doi: 10.1007/s00268-015-3328-6
Farges O, Bendersky N, Truant S et al (2017) The theory and practice of pancreatic surgery in France. Ann Surg 266:797–804
pubmed: 28885506
doi: 10.1097/SLA.0000000000002399
Atema JJ, Jilesen AP, Busch OR et al (2015) Pancreatic fistulae after pancreatic resections for neuroendocrine tumours compared with resections for other lesions. HPB (Oxford) 17(1):38–45
doi: 10.1111/hpb.12319
El Amrani M, Clement G, Truant S et al (2018) Failure-to-rescue in patients undergoing pancreatectomu: is hospital volume a standard for quality improvement programs? Nationwide analysis of 12,333 patients. Ann Surg 268(5):799–807
pubmed: 30048329
doi: 10.1097/SLA.0000000000002945
Cadiot G, Vuagnat A, Doukhan I et al (1999) Prognostic factors in patients with Zollinger–Ellison syndrome and multiple endocrine neoplasia type 1. Groupe d’Etude des Néoplasies Endocriniennes Multiples (GENEM and groupe de Recherche et d’Etude du Syndrome de Zollinger–Ellison (GRESZE). Gastroenterology 116(2):286–93
pubmed: 9922308
doi: 10.1016/S0016-5085(99)70124-1
Fraker DL, Norton JA, Alexander HR et al (1994) Surgery in Zollinger–Ellison syndrome alters the natural history of gastrinoma. Ann Surg. 220(3):320–8
pubmed: 7916560
pmcid: 1234386
doi: 10.1097/00000658-199409000-00008
Bartsch DK, Fendrich V, Langer P et al (2005) Outcome of duodenopancreatic resections in patients with multiple endocrine neoplasia type 1. Ann Surg 242(6):757–64 (discussion 764-6)
pubmed: 16327485
pmcid: 1409888
doi: 10.1097/01.sla.0000189549.51913.d8
Thevenon J, Bourredjem A, Faivre L et al (2013) Higher risk of death among MEN1 patients with mutations in the JunD interacting domain: a Groupe d’étude des Tumeurs Endocrines (GTE) cohort study. Hum Mol Genet 22(10):1940–1948
pubmed: 23376981
doi: 10.1093/hmg/ddt039
Anlauf M, Perren A, Klöppel G (2007) Endocrine precursor lesions and microadenomas of the duodenum and pancreas with and without MEN1: criteria, molecular concepts and clinical significance. Pathobiology 74(5):279–284
pubmed: 17890894
doi: 10.1159/000105810